NASDAQ:DERM - Dermira Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.95 +0.23 (+2.37 %) (As of 05/26/2019 04:00 PM ET)Previous Close$9.95Today's Range$9.70 - $10.0752-Week Range$6.00 - $15.48Volume425,068 shsAverage Volume1.61 million shsMarket Capitalization$534.00 millionP/E RatioN/ADividend YieldN/ABeta1.32 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California. Receive DERM News and Ratings via Email Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DERM Previous Symbol CUSIPN/A CIK1557883 Webhttp://www.dermira.com/ Phone650-421-7200Debt Debt-to-Equity Ratio4.36 Current Ratio7.13 Quick Ratio6.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.34 million Price / Sales12.61 Cash FlowN/A Price / Cash FlowN/A Book Value$1.39 per share Price / Book7.16Profitability EPS (Most Recent Fiscal Year)($5.24) Net Income$-221,540,000.00 Net Margins-510.47% Return on Equity-391.86% Return on Assets-53.34%Miscellaneous Employees333 Outstanding Shares53,668,000Market Cap$534.00 million Next Earnings Date8/5/2019 (Estimated) OptionableOptionable Dermira (NASDAQ:DERM) Frequently Asked Questions What is Dermira's stock symbol? Dermira trades on the NASDAQ under the ticker symbol "DERM." How were Dermira's earnings last quarter? Dermira Inc (NASDAQ:DERM) released its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($1.49) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.10) by $0.39. The biopharmaceutical company earned $2.45 million during the quarter, compared to analyst estimates of $2.63 million. Dermira had a negative return on equity of 391.86% and a negative net margin of 510.47%. View Dermira's Earnings History. When is Dermira's next earnings date? Dermira is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Dermira. What price target have analysts set for DERM? 9 Wall Street analysts have issued 12 month price objectives for Dermira's stock. Their forecasts range from $6.71 to $25.00. On average, they expect Dermira's share price to reach $19.0888 in the next twelve months. This suggests a possible upside of 91.8% from the stock's current price. View Analyst Price Targets for Dermira. What is the consensus analysts' recommendation for Dermira? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira. What are Wall Street analysts saying about Dermira stock? Here are some recent quotes from research analysts about Dermira stock: 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (5/8/2019) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $7 price target. The STING program currently contributes approximately 53% to our valuation (no contribution from early stage Lilly program currently) and the APRIL program approximately 43%, with the remainder coming from the anti-CD27 program being developed by Merck (MRK; not rated). Our target is based on our clinical net present value (NPV) model. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (5/8/2019) 3. Cantor Fitzgerald analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (5/3/2019) Has Dermira been receiving favorable news coverage? Media headlines about DERM stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Dermira earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Dermira's key competitors? Some companies that are related to Dermira include Portola Pharmaceuticals (PTLA), Insmed (INSM), AnaptysBio (ANAB), Endocyte (ECYT), Akcea Therapeutics (AKCA), Allakos (ALLK), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Tricida (TCDA), Pacira Biosciences (PCRX), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Nabriva Therapeutics (NBRV), Zogenix (ZGNX) and Prestige Consumer Healthcare (PBH). What other stocks do shareholders of Dermira own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Novavax (NVAX), Exelixis (EXEL), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), Celgene (CELG), Johnson & Johnson (JNJ), Cara Therapeutics (CARA), Karyopharm Therapeutics (KPTI) and Nektar Therapeutics (NKTR). Who are Dermira's key executives? Dermira's management team includes the folowing people: Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 67)Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 77)Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 51)Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 42)Mr. Christopher M. Griffith, Co-Founder and Chief Bus. & Strategy Officer (Age 43) Who are Dermira's major shareholders? Dermira's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (1.63%), Jacobs Levy Equity Management Inc. (1.42%), Vivo Capital LLC (1.30%), Renaissance Technologies LLC (1.01%), Rhenman & Partners Asset Management AB (0.93%) and Geode Capital Management LLC (0.85%). Company insiders that own Dermira stock include Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Matthew K Fust and Thomas G Wiggans. View Institutional Ownership Trends for Dermira. Which major investors are selling Dermira stock? DERM stock was sold by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, First Midwest Bank Trust Division, Dimensional Fund Advisors LP, JPMorgan Chase & Co., DekaBank Deutsche Girozentrale, Morgan Stanley, Metropolitan Life Insurance Co NY and Rhumbline Advisers. Company insiders that have sold Dermira company stock in the last year include Eugene A Bauer and Matthew K Fust. View Insider Buying and Selling for Dermira. Which major investors are buying Dermira stock? DERM stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Rhenman & Partners Asset Management AB, Renaissance Technologies LLC, Candriam Luxembourg S.C.A., Opaleye Management Inc., Jacobs Levy Equity Management Inc., Assenagon Asset Management S.A. and Macquarie Group Ltd.. Company insiders that have bought Dermira stock in the last two years include Fred B Craves and Thomas G Wiggans. View Insider Buying and Selling for Dermira. How do I buy shares of Dermira? Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Dermira's stock price today? One share of DERM stock can currently be purchased for approximately $9.95. How big of a company is Dermira? Dermira has a market capitalization of $534.00 million and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis. Dermira employs 333 workers across the globe. What is Dermira's official website? The official website for Dermira is http://www.dermira.com/. How can I contact Dermira? Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected] MarketBeat Community Rating for Dermira (NASDAQ DERM)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 290 (Vote Outperform)Underperform Votes: 267 (Vote Underperform)Total Votes: 557MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: Convertible Shares Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.